Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-16T05:46:46.489Z Has data issue: false hasContentIssue false

Implementation of an automated methicillin-resistant Staphylococcus aureus polymerase chain reaction screening intervention to guide discontinuation of vancomycin for pneumonia

Published online by Cambridge University Press:  01 December 2025

Reem Azem*
Affiliation:
University Hospitals of Cleveland (Cleveland Medical Center), Cleveland, OH, USA
Elie A. Saade
Affiliation:
University Hospitals of Cleveland (Cleveland Medical Center), Cleveland, OH, USACase Western Reserve University, Cleveland, OH, USA
Courtney Veltri
Affiliation:
University Hospitals of Cleveland (Cleveland Medical Center), Cleveland, OH, USA
Nicholas J. Newman
Affiliation:
University Hospitals of Cleveland (Cleveland Medical Center), Cleveland, OH, USA
Natalie Kolehmainen
Affiliation:
University Hospitals of Cleveland (Ahuja Medical Center), Cleveland, OH, USA
Khoi Dang
Affiliation:
University Hospitals of Cleveland (Ahuja Medical Center), Cleveland, OH, USA
Lisa M. Stempak
Affiliation:
Case Western Reserve University, Cleveland, OH, USACleveland Clinic, Cleveland, OH, USA
Brigid M. Wilson
Affiliation:
VA Northeast Ohio Healthcare System, Cleveland, OH, USA
Leila S. Hojat
Affiliation:
University Hospitals of Cleveland (Cleveland Medical Center), Cleveland, OH, USACase Western Reserve University, Cleveland, OH, USA
*
Corresponding author: Reem Azem; Email: reemazem131@gmail.com

Abstract

Background:

Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogen commonly implicated in pneumonia for which vancomycin is often used to cover empirically. Our study examined the impact of a pharmacy-based automatic MRSA polymerase chain reaction (PCR) nares intervention.

Methods:

We included patients prescribed vancomycin for pneumonia and defined three cohorts: pre-intervention (Cohort 1), post-test implementation (Cohort 2), and post-test implementation with electronic medical record (EMR) enhancements and active stewardship involvement (Cohort 3). The primary outcome was total duration of vancomycin treatment. We performed a desirability of outcome ranking with response adjusted for duration of antibiotic risk (DOOR/RADAR) analysis to prioritize clinical outcomes including adverse events, escalation of care, and death.

Results:

The median duration of vancomycin therapy decreased between Cohorts 1 and 2 (55 versus 47 hours, p = 0.15), with a greater decrease detected among the subset of Cohort 2 patients from whom the PCR test was actually collected (42 hours, p = 0.035). Duration of therapy was lowest in Cohort 3 (22.3 hours, p < 0.001). In the DOOR/RADAR analysis, no meaningful difference in clinical outcomes was detected between Cohorts 1 and 2 (p = 0.55). Cohort 3 had substantially better ranked outcomes when compared to Cohorts 1 and 2 (p < 0.001).

Conclusion:

Vancomycin treatment duration was shorter in patients after a pharmacy-directed, EMR-based MRSA PCR intervention was implemented, with a greater response after implementation of additional EMR enhancements and active stewardship involvement, improving test collection rate and result response. This study will help inform future interventions pairing automated EMR-based interventions with stewardship team efforts.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Figure 1.Flowchart of intervention phases with descriptions of key components defining each phase.

Figure 1

Table 1.Patient and hospital characteristics among each cohort. Values are shown as n (percent) unless otherwise specified

Figure 2

Table 2.Cohort time endpoints. Cohort 1 refers to preintervention period, Cohort 2 to first postintervention period, Cohort 3 to second postintervention period. Cohort results are in the first 3 columns. The last 3 columns provide subgroup analyses. Times are in median hours with interquartile range in parentheses. Pairwise comparisons of Cohort 1 versus other cohorts total time to vancomycin discontinuation with a p value of<0.05 are in bold. Additional p values for comparisons of Cohort 3 community versus academic sites are included

Figure 3

Figure 2.Distribution of the clinical outcome categories among each cohort. Abbreviations: AE, adverse events (acute kidney injury, infusion reaction, or severe antibiotic reaction); O2, oxygen requirement.

Figure 4

Figure 3.Boxplots for median time to vancomycin discontinuation in hours within each clinical outcome category for both pre- and postintervention groups. Left boxplot within each category corresponds to preintervention group (Cohort 1), second boxplot corresponds to the first postintervention group (Cohort 2), and the third boxplot corresponds to the second intervention group (Cohort 3), and right boxplot designated with a star corresponds to the second intervention group after excluding community cases (Cohort 3 academic). Outliers are not shown. Abbreviations: AE, adverse events (acute kidney injury, infusion reaction, or severe antibiotic reaction); O2, oxygen requirement.